All stock lists
Unlock the score
BlossomHill Therapeutics, Inc. (NASDAQ:BLSM)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
16.12+1.49 (+10.18%)
Market cap
$469M
Insider Score
Health Score
Analyst consensus
Listed since
Aug 7, 2026
Website
Insider Score
/ 100
BLSM Insider Score
BlossomHill Therapeutics, Inc. has a live Insider Score.
Scored on 7 qualifying trades from 6 insiders in the last 90 days.
BLSM analyst forecast
BLSM analyst consensus
Moderate Buy2 ratings
Buy 2 Hold 0 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
BLSM 12-month price target
$35.00+115.4% upsideaverage of 1 firm
$35.00High
$35.00Low
Best analysts covering BLSM
No firm covering BLSM has enough calls with a finished 1Y holding period to rank yet.
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
BLSM analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | Guggenheim | Buy | — | — | Reiterated | 2026-09-21 |
| — | Leerink Partners | Outperform | — | — | Reiterated | 2026-09-21 |
| H.C. Wainwright | — | $35.00 | +91.3% | — | 2026-09-01 |
BLSM earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-09-18 | -0.93 | -8.75 | $0 | $0 |
| 2026-12-18 | -0.93 | 0.00 | $0 | $0 |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.